[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100459117":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":23,"centralContacts":27,"locations":33,"responsibleParty":49,"collaborators":10,"id":52,"slug":10,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":10,"enrollmentInfo":61,"targetDuration":64,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":10,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Odense University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"COLA 1: Locally advanced non-small-cell lung cancer",null,"Patients with locally advanced non-small-cell lung cancer treated with radiotherapy alone or in combination with chemotherapy with curative intent. Patients are included before initiation of the treatment. A Cardiac MR and ECG are performed at the beginning of the treatment, and at 6, 12, and 24 months after radiotherapy.",[13],"Other: Chemoradiotherapy",{"label":15,"type":10,"description":16,"interventionNames":17},"COLA 2 Locally advanced non-small-cell lung cancer","Patients with locally advanced non-small-cell lung cancer treated with radiotherapy alone or in combination with chemotherapy with curative intent. Patients not included in COLA 1 cohort are offered one cardiac MR and ECG between 12-24 months after radiotherapy treatment.",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"Chemoradiotherapy","Cardiac Magnetic Resonance scan and ECG",[9,15],[24],{"name":25,"affiliation":5,"role":26},"Tine Schytte, Professor","PRINCIPAL_INVESTIGATOR",[28],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Agon AO Olloni, MD","CONTACT","42206617","agon.olloni@rsyd.dk",[34],{"facility":5,"status":35,"city":36,"state":10,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Odense C","5000","Denmark",{"type":40,"coordinates":41},"Point",[42,43],10.39538,55.40841,{"lat":43,"lon":42},[46],{"name":47,"role":30,"phone":48,"phoneExt":10,"email":32},"Agon Olloni, MD","+4542206617",{"type":26,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Agon Olloni","Principal Investigator, MD, Phd Student","100459117",false,"NCT05258448","COr Loco-regional Advanced Lung Cancer Treated With Chemo-radiotherapy (COLA)","The Effect of Radiotherapy on the Heart in Loco-regional Advanced NSCLC Patients Treated With Definitive Radiotherapy Measured by Cardiac MR","COLA","Inclusion Criteria:\n\n* Age ≥ 18 Years\n* Inoperable and histologically\u002Fcytologically verified NSCLC.\n* Planned treatment with curative intent.\n* Capable of completing study procedures ECG and Cardiac MR.\n* Able of giving written and informed consent before study procedures are initiated.\n\nExclusion Criteria:\n\n* Vulnerable patients.\n* Patients with operable devices as pacemaker\u002FICD and cochlear implant or other conditions where MR scan is contraindicated.\n* Claustrophobia.","ALL","18 Years",{"count":62,"type":63},100,"ESTIMATED","2 Years","OBSERVATIONAL","Patients with loco-regional NSCLC planned for curative treatment with chemoradiotherapy will be invited to participate in a prospective study; besides routine treatment, the patients will be followed with an ECG and cardiac MR for at least two years after radiotherapy treatment.",[68,69,70,71,72],"Cardiac Toxicity","Lung Cancer Stage III","Lung Cancer Stage II","Radiation Toxicity","Cardiac Disease","2023-12-05",{"date":75,"type":76},"2023-12-06","ACTUAL",{"date":78,"type":76},"2015-08",{"date":80,"type":63},"2026-10",{"name":5,"class":6},1]